Overview

Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa

Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and efficacy of Apremilast in subjects with moderate Hidradenitis Suppurativa (HS).
Phase:
Phase 2
Details
Lead Sponsor:
Florida Academic Dermatology Centers
Treatments:
Apremilast
Thalidomide